Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/KATP channel pathway and PPARγ receptors.
Int J Neurosci
; 131(10): 1004-1011, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-32408781
ABSTRACT
OBJECTIVE:
The leukotrienes are inflammatory mediators. In the present study, the analgesic role of local montelukast, a cysteinyl leukotriene receptor antagonist, and the possible involvement of L-arginine/NO/cGMP/KATP channel pathway and PPARγ receptors was assessed in the formalin test in rats. METHODS ANDRESULTS:
The local administration of montelukast into the hind paw produced dose-related analgesia during both phases of the formalin test. Furthermore, pre-treatment with L-NAME, methylene blue, and glibenclamide prevented montelukast (10 µg/paw)-induced antinociception in both early and late phases of the test. Moreover, the local L-arginine and diazoxide before the sub-effective dose of montelukast (3 µg/paw) produced an analgesic effect. Also, local GW-9662 blocked antinociception induced by montelukast plus pioglitazone (10 µg/paw).CONCLUSION:
In conclusion, montelukast produced peripheral analgesia through PPARγ receptors and activation of the L-arginine/NO/cGMP/KATP channel pathway, with potential for a new topical analgesic drug.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Arginina
/
Quinolinas
/
Sulfetos
/
GMP Cíclico
/
Antagonistas de Leucotrienos
/
Ciclopropanos
/
PPAR gama
/
Canais KATP
/
Dor Nociceptiva
/
Analgesia
Limite:
Animals
Idioma:
En
Revista:
Int J Neurosci
Ano de publicação:
2021
Tipo de documento:
Article